Canada markets closed

NurExone Biologic Inc. (NRX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5900-0.0100 (-1.67%)
At close: 03:36PM EDT
Currency in CAD

Valuation Measures4

Market Cap (intraday) 38.83M
Enterprise Value 38.12M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)149.70
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -10.58

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 384.38%
S&P500 52-Week Change 322.38%
52 Week High 31.1900
52 Week Low 30.1850
50-Day Moving Average 30.7022
200-Day Moving Average 30.4093

Share Statistics

Avg Vol (3 month) 3172.16k
Avg Vol (10 day) 329.37k
Shares Outstanding 565.81M
Implied Shares Outstanding 665.81M
Float 862.51M
% Held by Insiders 16.05%
% Held by Institutions 10.00%
Shares Short (Apr 15, 2024) 444
Short Ratio (Apr 15, 2024) 40
Short % of Float (Apr 15, 2024) 4N/A
Short % of Shares Outstanding (Apr 15, 2024) 40.00%
Shares Short (prior month Mar 15, 2024) 4493

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-92.09%
Return on Equity (ttm)-318.51%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -3.65M
Net Income Avi to Common (ttm)-3.64M
Diluted EPS (ttm)-0.1100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)541k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)1.2M
Total Debt/Equity (mrq)634.39%
Current Ratio (mrq)1.04
Book Value Per Share (mrq)0.00

Cash Flow Statement

Operating Cash Flow (ttm)-2.94M
Levered Free Cash Flow (ttm)-2.84M